Skip to main content

Biochemically Equivalent Substitutive Technology for Stem Cells

Objective

Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factors such as serum and purified proteins, often sourced from vertebrate animal tissue. These factors contribute to variations in cell properties and differentiation potential which impact on the efficacy of cell culture. More worryingly these factors are potential avenues for the introduction of unknown or known pathogens with the capacity to infect transplant recipients thereby becoming communicable to the general population. Especially concerning is the opportunity for transmission of potentially lethal diseases across vertebrate species for which there are no known cures. The propensity of primitive stem cell populations to spontaneously differentiate is an added challenge which generally necessitates cumbersome manipulation of cells by skilled operators involving daily assessment, media replenishment and or cell passaging by physical dissociation. Realising the promise of stem cells and their derivatives for clinical and industrial applications therefore requires the evolution of new paradigms for cell culture which maximise chemical definition, minimise the involvement of skilled operators, and offer non-invasive modulation of cells by biocompatible means. The aim of this proposal is to discover and integrate with established and new cell culture technology, synthetic and non-vertebrate derived purified molecules with a capacity to mimic the functional properties of crude biological reagents currently used to control the behaviour of embryonic and adult stem cells, most notably affecting self-renewal, pluripotency, lineage specification and stability following cryopreservation. These will be validated to deliver new culture paradigms designed for compliance with Good Manufacturing Practice Standards necessary for the delivery of clinical grade cells for therapeutic use.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells

Call for proposal

FP7-HEALTH-2007-B
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

THE UNIVERSITY OF EDINBURGH
Address
Old College, South Bridge
EH8 9YL Edinburgh
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 372 211
Administrative Contact
Angela Noble (Ms.)

Participants (7)

Roslin Cells Ltd.
United Kingdom
EU contribution
€ 107 582
Address
C/o Roslin Foundation, Wallace Building, Roslin Biocentre
EH25 9PP Roslin, Midlothian
Activity type
Research Organisations
Administrative Contact
Kathryn Reilly (Mrs.)
Administrative Contact
Janet Downie (Ms.)
Administrative Contact
Kathryn Reilly (Mrs.)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 509 600
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
Administrative Contact
Nadine Brochet (Ms.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 240 534
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Dominique Pella (Mr.)
UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 447 600
Address
Venusberg-campus 1
53127 Bonn
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Beate Gieselmann (Ms.)
BIONEER A/S
Denmark
EU contribution
€ 154 950
Address
Kogle Alle 2
2970 Hoersholm
Activity type
Research Organisations
Administrative Contact
Lars Hagsholm Pedersen (Dr.)
UNIVERSITE DE LIEGE
Belgium
EU contribution
€ 98 400
Address
Place Du 20 Aout 7
4000 Liege
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Isabelle Halleux (Dr.)
GLYCOMAR LIMITED
United Kingdom
EU contribution
€ 68 190
Address
Dunstaffnage Marine Laboaratory European Centre For Marine Biotechnology Dunbeg Argyll
PA37 1QA Oban
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Charles Bavington (Dr.)